



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT W
WX0000003826 F 12/05/1988 34 Y

Referral Testing

Collected: 08/29/2023 08:44 Received: 08/29/2023 08:44

Table with 6 columns: Test Name, Result, Flag, Ref-Ranges, Units, Site. Row 1: Tiagabine (Gabatril), Serum/Plasma, 130, ng/mL, NMRL

Reporting Limit: 4.0 ng/mL
Synonym(s): Gabitril(R)
The relationship between tiagabine plasma concentrations and the clinical response is not currently understood. However, trough plasma concentrations from 1-234 ng/mL were reported in one major controlled clinical study at doses of 30 to 56 mg per day. A diurnal effect on the pharmacokinetics of tiagabine has been noted; mean steady-state trough concentrations were 40% lower in the evening than in the morning.
Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.

Testing performed at NMS Labs, Inc.
200 Welsh Road
Horsham, PA 19044-2208
CLIA 39D0197898

Reported Date: 2023.08.29 8:52

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

F229000003 Ordered By: KAJAL SITWALA, MD, PhD
WX0000003826 WX00000000002353
Printed D&T: 08/29/23 08:53

Kajal V. Sitwala, MD, PhD - Medical Director
Form: MM RL1
PAGE 1 OF 1